Projects per year
Fingerprint
Dive into the research topics where Wilson Gonsalves is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Assessment of Metabolites Among Asymptomatic Precursor and Malignant Monoclonal Gammopathies
3/1/21 → 2/28/25
Project: Research project
-
Dysregulation of Glutamine Metabolism in the Pathogenesis of Multiple Myeloma
7/1/17 → 6/30/20
Project: Research project
-
An Open-Label Phase I Study of Metformin and Nelfinavir in Combination With Bortezomib in Patients With Relapsed and Refractory Multiple Myeloma
Alodhaibi, I., Ailawadhi, S., Burbano, G. P., O'Brien, P. J., Buadi, F. K., Hayman, S., Kumar, S. K. & Gonsalves, W. I., 2024, (Accepted/In press) In: Clinical Lymphoma, Myeloma and Leukemia.Research output: Contribution to journal › Article › peer-review
-
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma
Alhaj Moustafa, M., Parrondo, R., Abdulazeez, M. F., Roy, V., Sher, T., Alegria, V. R., Warsame, R. M., Fonseca, R., Rasheed, A., Gonsalves, W. I., Kourelis, T., Kapoor, P., Buadi, F. K., Dingli, D., Hayman, S. R., Reeder, C. B., Chanan-Khan, A. A. & Ailawadhi, S., Jan 1 2024, In: Anti-cancer drugs. 35, 1, p. 63-69 7 p.Research output: Contribution to journal › Article › peer-review
-
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
Goel, U., Charalampous, C., Kapoor, P., Binder, M., Buadi, F. K., Dingli, D., Dispenzieri, A., Fonder, A., Gertz, M. A., Gonsalves, W. I., Hayman, S. R., Hobbs, M. A., Hwa, Y. L., Kourelis, T., Lacy, M. Q., Leung, N., Lin, Y., Warsame, R. M., Kyle, R. A., Rajkumar, S. V., & 1 others , Dec 2024, In: Blood cancer journal. 14, 1, 55.Research output: Contribution to journal › Article › peer-review
Open Access -
Predictors and Impact of Timing of Disease Progression Following Primary Therapy in Multiple Myeloma
Goldman-Mazur, S., Visram, A., Rajkumar, S. V., Kapoor, P., Dispenzieri, A., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Hayman, S. R., Dingli, D., Kourelis, T., Gonsalves, W., Warsame, R., Muchtar, E., Leung, N., Kyle, R. A. & Kumar, S. K., Mar 2024, In: Clinical Lymphoma, Myeloma and Leukemia. 24, 3, p. e104-e111.e1Research output: Contribution to journal › Article › peer-review
-
A phase 1/2 of carfilzomib and melphalan conditioning for autologous stem cell transplantation for multiple myeloma (CARAMEL)
Visram, A., Hayman, S. R., Dispenzieri, A., Kapoor, P., Lacy, M. Q., Gertz, M. A., Buadi, F. K., Dingli, D., Warsame, R., Kourelis, T., Cook, J., Binder, M., Gonsalves, W., Muchtar, E., Leung, N., Roy, V., Rajkumar, S. V. & Kumar, S., Aug 2023, In: American journal of hematology. 98, 8, p. 1277-1285 9 p.Research output: Contribution to journal › Article › peer-review